ketamine has been researched along with Genetic Predisposition in 10 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketamine was not effective in facilitating avoidance extinction or in modifying LTP in WKY non-responders." | 5.48 | Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders. ( Fortress, AM; Pang, KCH; Smith, IM, 2018) |
| " To generate and validate a new substrain of rats with signs related to schizophrenia, we used selective breeding after postweaning social isolation and chronic ketamine treatment through several generations of animals and compared the subsequent strain to naive rats that were not genetically manipulated." | 3.79 | Characterization of gene-environment interactions by behavioral profiling of selectively bred rats: the effect of NMDA receptor inhibition and social isolation. ( Adam, G; Benedek, G; Horvath, G; Kekesi, G; Keri, S; Petrovszki, Z; Tuboly, G, 2013) |
| "Subjects with a family history of alcohol dependence showed significantly greater improvement in MADRS scores compared with subjects who had no family history of alcohol dependence." | 2.74 | Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. ( Brutsche, N; Luckenbaugh, DA; Manji, HK; Moral, JR; Phelps, LE; Zarate, CA, 2009) |
| "Chronic postsurgical pain (CPSP) is an important and well recognized cause of much long-term suffering, which in some cases may be preventable and affects many people living with cancer." | 2.58 | Chronic postsurgical pain and cancer: the catch of surviving the unsurvivable. ( Bhaskar, A; Humble, SR; Jayaweera, A; Varela, N, 2018) |
| "Ketamine was not effective in facilitating avoidance extinction or in modifying LTP in WKY non-responders." | 1.48 | Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders. ( Fortress, AM; Pang, KCH; Smith, IM, 2018) |
| "The ketamine-treated sample included 157 unrelated European subjects with major depressive disorder (MDD) or bipolar disorder (BD)." | 1.48 | Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. ( Akula, N; Charney, DS; Drevets, W; Furey, M; Grunebaum, M; Guo, W; Henter, I; Kadriu, B; Machado-Vieira, R; Mann, JJ; Mathew, S; McMahon, FJ; Merikangas, K; Murrough, JW; Oquendo, MA; Shugart, YY; Yuan, P; Zarate, CA, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, QS | 1 |
| Wajs, E | 1 |
| Ochs-Ross, R | 1 |
| Singh, J | 1 |
| Drevets, WC | 1 |
| Humble, SR | 1 |
| Varela, N | 1 |
| Jayaweera, A | 1 |
| Bhaskar, A | 1 |
| Fortress, AM | 1 |
| Smith, IM | 1 |
| Pang, KCH | 1 |
| Guo, W | 1 |
| Machado-Vieira, R | 1 |
| Mathew, S | 1 |
| Murrough, JW | 1 |
| Charney, DS | 1 |
| Grunebaum, M | 1 |
| Oquendo, MA | 1 |
| Kadriu, B | 1 |
| Akula, N | 1 |
| Henter, I | 1 |
| Yuan, P | 1 |
| Merikangas, K | 1 |
| Drevets, W | 1 |
| Furey, M | 1 |
| Mann, JJ | 1 |
| McMahon, FJ | 1 |
| Zarate, CA | 3 |
| Shugart, YY | 1 |
| Xu, K | 1 |
| Lipsky, RH | 1 |
| Niciu, MJ | 1 |
| Luckenbaugh, DA | 2 |
| Ionescu, DF | 1 |
| Richards, EM | 1 |
| Vande Voort, JL | 1 |
| Ballard, ED | 1 |
| Brutsche, NE | 1 |
| Furey, ML | 1 |
| Yoon, G | 1 |
| Pittman, B | 1 |
| Limoncelli, D | 2 |
| Krystal, JH | 2 |
| Petrakis, IL | 2 |
| Phelps, LE | 1 |
| Brutsche, N | 1 |
| Moral, JR | 1 |
| Manji, HK | 1 |
| Petrovszki, Z | 1 |
| Adam, G | 1 |
| Tuboly, G | 1 |
| Kekesi, G | 1 |
| Benedek, G | 1 |
| Keri, S | 1 |
| Horvath, G | 1 |
| Gueorguieva, R | 1 |
| Jatlow, P | 1 |
| Boutros, NN | 1 |
| Trevisan, L | 1 |
| Gelernter, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NMDA Dysregulation in Individuals With a Family Vulnerability to Alcoholism[NCT00588952] | 99 participants (Actual) | Interventional | 2001-03-31 | Completed | |||
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| Study of the Efficacity of the Systemic Ketamine for the Improvement of Post-Operative Analgesia After ORL Carcinological Surgery at the Alcohol-Dependent Patient.[NCT00329394] | Phase 3 | 56 participants (Anticipated) | Interventional | 2006-04-30 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 15 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 24.74 | 1.36 |
| Family History Positive | 18.96 | 2.46 |
Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 45 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 25.06 | 1.64 |
| Family History Positive | 18.36 | 1.46 |
Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 80 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 9.99 | 0.92 |
| Family History Positive | 7.46 | 1.07 |
Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 0.96 | 1.25 |
| Family History Positive | 0.63 | 0.71 |
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 15 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 14.58 | 1.82 |
| Family History Positive | 22.39 | 1.82 |
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 45 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 9.06 | 1.64 |
| Family History Positive | 15.4 | 1.54 |
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 80 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 3.02 | 2.12 |
| Family History Positive | 3.81 | 1.61 |
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 2.43 | 2.88 |
| Family History Positive | 3.78 | 2.36 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
2 reviews available for ketamine and Genetic Predisposition
| Article | Year |
|---|---|
Chronic postsurgical pain and cancer: the catch of surviving the unsurvivable.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Chronic Pain; Drug Therapy, Combination; Gabapentin; Ge | 2018 |
Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans.
Topics: Excitatory Amino Acid Antagonists; Gene Expression Regulation; Genetic Predisposition to Disease; Hu | 2015 |
4 trials available for ketamine and Genetic Predisposition
| Article | Year |
|---|---|
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Topics: Adolescent; Adult; Aged; Alcohol-Related Disorders; Antidepressive Agents; Depressive Disorder, Majo | 2014 |
Familial Alcoholism Risk and the Ratio of Stimulant to Sedative Effects of Ketamine.
Topics: Adult; Alcoholism; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Genetic Predispos | 2016 |
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Topics: Adolescent; Adult; Aged; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Excitatory A | 2009 |
Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism.
Topics: Adult; Affect; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Brief Psychiatric Rating Scale; | 2004 |
4 other studies available for ketamine and Genetic Predisposition
| Article | Year |
|---|---|
Genome-wide association study and polygenic risk score analysis of esketamine treatment response.
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Genetic Markers; Genetic Predisposition t | 2020 |
Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Avoidance Learning; Extinction, Psychological; Gene | 2018 |
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Female | 2018 |
Characterization of gene-environment interactions by behavioral profiling of selectively bred rats: the effect of NMDA receptor inhibition and social isolation.
Topics: Acoustic Stimulation; Animals; Behavior, Animal; Breeding; Disease Models, Animal; Gene-Environment | 2013 |